Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
  • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
  • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
  • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
  • C07D333/64—Oxygen atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
  • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• Estrogens are the primary female hormones responsible for the development and regulation of the female reproductive system and secondary female sex characteristics. Estrogens also have pleotropic roles in protein synthesis, coagulation, lipid balance, fluid balance, melanin, gastrointestinal track function, lung function, cognition, immune response and heart disease, among others.
• Ri is selected from hydroxyl, hydrogen, halogen, -0(Ci-C 6 alkyl), -OC(0)(Ci-C 6 alkyl), -OC(0)C 6 H 5 , -OC(0)0(Ci-Ce alkyl), -OC(0)OC 6 H 5 and -OS0 2 (C2-C 6 alkyl);
• R.3 is independently selected at each occurrence from hydrogen, halogen, -CN,
• FIG. 2A, FIG. 2B, FIG. 2C, and FIG. 2D are graphs of the efficacy of Compounds 11, 12, and 13 compared to known compound GDN-0810 against tamoxifen-resistant MCF-7:WS8 cells.
• the y-axis is normalized DNA content in percent and the x-axis is the concentration of compound measured in log(molar) units.
• the graph shows that representative compounds have sub- nanomolar efficacy in tamoxifen-resistant MCF-7:WS8 cells using DNA content assay.
• bicyclic heteroaryl include, but are not limited to, benzimidazolyl, benzofuranyl, benzothienyl, benzoxadiazolyl, benzoxathiadiazolyl, benzothiazolyl, cinnolinyl, 5,6-dihydroquinolin-2-yl, 5,6-dihydroisoquinolin-l-yl, furopyridinyl, indazolyl, indolyl, isoquinolinyl, naphthyridinyl, quinolinyl, purinyl, 5,6,7,8-tetrahydroquinolin- 2-yl, 5,6,7,8-tetrahydroquinolin-3-yl, 5,6,7,8-tetrahydroquinolin-4-yl, 5,6,7,8- tetrahydroisoquinolin-l-yl, thienopyridinyl, 4,5,6,7-tetrahydrobenzo
• Ring B is phenyl, naphthyl, quinolinyl, 5- or 6- membered monocyclic heteroaryl or 7-, 8-, 9- or 10 membered bicyclic heterocyclyl;
• this invention provides a compound of Formula C:
• n O, 1, 2, 3, or 4;
• Ri is selected from hydroxyl, hydrogen, halogen, -0(Ci-C 6 alkyl), -OC(0)(Ci-C 6 alkyl), -OC(0)C 6 H 5 , -OC(0)0(Ci-Ce alkyl), -OC(0)OC 6 H 5 and -OS0 2 (C 2 -C 6 alkyl);
• R 2 is selected from -COOH, -NH(CO)COOH and
• R 3 is independently selected at each occurrence from hydrogen, halogen, -CN,
• n one embodiment m is 2 and n is i .
• Additional representative compounds of the invention include, but are not limited to compounds of formula:
• a biological buffer can be any solution which is pharmacologically acceptable and which provides the formulation with the desired pH, i.e., a pH in the physiologically acceptable range.
• buffer solutions include saline, phosphate buffered saline, Tris buffered saline, Hank's buffered saline, and the like.
• the composition will generally take the form of a tablet, capsule, a softgel capsule or can be an aqueous or nonaqueous solution, suspension or syrup. Tablets and capsules are typical oral administration forms. Tablets and capsules for oral use can include one or more commonly used carriers such as lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added.
• the compositions of the disclosure can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol and the like.
• Ointments are semisolid preparations which are typically based on petrolatum or other petroleum derivatives.
• Creams containing the selected active agent are, as known in the art, viscous liquid or semisolid emulsions, either oil-in-water or water-in-oil.
• Cream bases are water-washable, and contain an oil phase, an emulsifier and an aqueous phase.
• the oil phase also sometimes called the "internal" phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol.
• the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant.
• the method of treatment may cause partial or complete regression of a tamoxifen resistant cancer or tumor.
• the method of treatment may cause partial or complete regression of a triple negative breast cancer.
• a compound of the present invention is used for hormone therapy.
• anti-estrogen compounds include: SERMS such as anordrin, adoxifene, broparestriol, chlorotrianisene, clomiphene citrate, cyclofenil, lasofoxifene, ormeloxifene, raloxifene, tamoxifen, toremifene, and fulvestrant; aromatase inhibitors such as aminoglutethimide, testolactone, anastrozole, exemestane, fadrozole, formestane, and letrozole; and antigonadotropins such as leuprorelin, cetrorelix, allylestrenol, chloromadinone acetate, cyproterone acetate, delmadinone acetate, dydrogesterone, medroxyprogesterone acetate, megestrol acetate, nomegestrol acetate, norethisterone acetate, progestrol acetate
• RAS inhibitors include but are not limited to Reolysin and siG12D LODER.
• ALK inhibitors include but are not limited to Crizotinib, AP26113, and LDK378.
• HSP inhibitors include but are not limited to Geldanamycin or 17-N-Allylamino-17-demethoxygeldanamycin (17AAG), and Radicicol.
• a compound described herein is administered in combination with letrozole and/or tamoxifen.
• Other chemotherapeutic agents that can be used in combination with the compounds described herein include, but are not limited to, chemotherapeutic agents that do not require cell cycle activity for their anti -neoplastic effect.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Physical Education & Sports Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Rheumatology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines Containing Plant Substances (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Steroid Compounds (AREA)
• Compounds Of Unknown Constitution (AREA)

Priority Applications (22)

Applications Claiming Priority (4)

Publications (1)

Family

ID=59013340

Family Applications (2)

Family Applications After (1)

Country Status (26)

Cited By (3)

Families Citing this family (12)

Citations (63)

Family Cites Families (41)

• 2016
  • 2016-12-09 DK DK16874012.4T patent/DK3386500T3/da active
  • 2016-12-09 ES ES16874012T patent/ES2935125T3/es active Active
  • 2016-12-09 MX MX2018007079A patent/MX373946B/es active IP Right Grant
  • 2016-12-09 PL PL16874012.4T patent/PL3386500T3/pl unknown
  • 2016-12-09 US US15/375,049 patent/US20170166551A1/en not_active Abandoned
  • 2016-12-09 EP EP16874015.7A patent/EP3386968B1/en active Active
  • 2016-12-09 CN CN201680071852.7A patent/CN108495628B/zh active Active
  • 2016-12-09 HU HUE16874012A patent/HUE061065T2/hu unknown
  • 2016-12-09 HR HRP20221462TT patent/HRP20221462T1/hr unknown
  • 2016-12-09 EP EP16874012.4A patent/EP3386500B1/en active Active
  • 2016-12-09 SI SI201631640T patent/SI3386500T1/sl unknown
  • 2016-12-09 RS RS20221118A patent/RS63791B1/sr unknown
  • 2016-12-09 MX MX2020006991A patent/MX393926B/es unknown
  • 2016-12-09 SM SM20230018T patent/SMT202300018T1/it unknown
  • 2016-12-09 RU RU2018125046A patent/RU2747802C2/ru active
  • 2016-12-09 PT PT168740124T patent/PT3386500T/pt unknown
  • 2016-12-09 NZ NZ743651A patent/NZ743651A/en unknown
  • 2016-12-09 WO PCT/US2016/066023 patent/WO2017100712A1/en not_active Ceased
  • 2016-12-09 US US15/374,966 patent/US10118910B2/en active Active
  • 2016-12-09 JP JP2018529925A patent/JP6920709B2/ja active Active
  • 2016-12-09 EA EA201891376A patent/EA038180B1/ru unknown
  • 2016-12-09 KR KR1020187019088A patent/KR102785173B1/ko active Active
  • 2016-12-09 CA CA3008020A patent/CA3008020C/en active Active
  • 2016-12-09 AU AU2016366680A patent/AU2016366680B2/en active Active
  • 2016-12-09 BR BR112018011607-6A patent/BR112018011607B1/pt active IP Right Grant
  • 2016-12-09 LT LTEPPCT/US2016/066023T patent/LT3386500T/lt unknown
  • 2016-12-09 WO PCT/US2016/066026 patent/WO2017100715A1/en not_active Ceased
  • 2016-12-09 CN CN201680071904.0A patent/CN108699024B/zh active Active
• 2018
  • 2018-05-23 IL IL259566A patent/IL259566B/en unknown
  • 2018-05-23 ZA ZA2018/03422A patent/ZA201803422B/en unknown
  • 2018-10-24 US US16/169,812 patent/US10377735B2/en active Active
• 2019
  • 2019-05-28 US US16/424,240 patent/US11072595B2/en active Active
  • 2019-08-09 US US16/537,079 patent/US10807964B2/en active Active
• 2020
  • 2020-05-22 ZA ZA2020/03023A patent/ZA202003023B/en unknown
  • 2020-10-19 US US17/074,550 patent/US11447461B2/en active Active
• 2021
  • 2021-07-14 JP JP2021116705A patent/JP2021169498A/ja active Pending
  • 2021-07-26 US US17/385,748 patent/US12054469B2/en active Active
• 2022
  • 2022-12-06 CY CY20221100768T patent/CY1125767T1/el unknown

Patent Citations (68)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events